Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Clinical Oncology

• Publication date

  1994-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1994.12.6.1245PMID 7515413
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Management of fever in patients with cancer and treatment-induced neutropenia.

  1993cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.

  1993cited by this paper
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1992cited by this paper
• The colony-stimulating factors. An overview.

  1992cited by this paper
• Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

  1992cited by this paper
• G-CSF for fever and neutropenia induced by chemotherapy.

  1992cited by this paper
• The development of granulocyte colony-stimulating factor in its various clinical applications.

  1992cited by this paper
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

  1991cited by this paper
• Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies.

  1991cited by this paper
• The role of granulocyte colony-stimulating factor in cancer chemotherapy.

  1991cited by this paper
• Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.

  1991cited by this paper
• Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.

  1991cited by this paper
• Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study.

  1991cited by this paper
• Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide.

  1991cited by this paper
• Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.

  1991cited by this paper
• Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.

  1990cited by this paper
• Rapid estimation of hospital charges in patients with leukemia. Validation of a multivariate prediction model.

  1989cited by this paper
• Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy.

  1988cited by this paper
• Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.

  1988cited by this paper
• Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.

  1987cited by this paper
• Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

  1987cited by this paper
• A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1987cited by this paper
• Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.

  1987cited by this paper
• Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

  1987cited by this paper
• Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung.

  1986cited by this paper
• Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.

  1986cited by this paper
• Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.

  1986cited by this paper
• Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC lung cancer working party (Belgium)

  1985cited by this paper
• Adriamycin, cyclophosphamide, and etoposide (VP‐16–213) in extensive‐stage small cell lung cancer

  1984cited by this paper
• Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung.

  1981cited by this paper

• The evolution of value with filgrastim in oncology.

  2019cites this paper
• Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

  2017cites this paper
• Chemotherapy for Advanced Non-small Cell Lung Cancer.

  2016cites this paper
• Myelo-protective and haematopoietic effects of seed extract fractions of Phoenix dactylifera in Wistar rats

  2016cites this paper
• Assessing the Relevance of Outcomes Data for Colony-Stimulating Factors

  2015cites this paper
• Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

  2014cites this paper
• 34 – Disorders of Blood Cell Production in Clinical Oncology

  2014cites this paper
• Neutropenia and G-CSF in lymphoproliferative diseases

  2013cites this paper
• Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.

  2012cites this paper
• Pharmacoeconomic Evaluation of Lenograstim

  2012cites this paper
• Economic evaluations of granulocyte colony-stimulating factor

  2012cites this paper
• Myelo-protective activity of aqueous and methanolic leaf extracts of vitex doniana in cyclophosphamide-induced myelo-suppression in wistar rats

  2011cites this paper
• Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review.

  2010cites this paper
• Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.

  2009cites this paper
• Myeloprotective effects of rosiglitazone, an insulin sensitizer, on 5-fluorouracil-induced toxicity

  2007cites this paper
• Pharmacoeconomics of Systemic Therapies for Lung Cancer

  2006cites this paper
• Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia

  2006cites this paper
• Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer

  2005cites this paper
• The Treatment of Elderly Patients with Aggressive Non-Hodgkin’s Lymphoma

  2005cites this paper
• Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.

  2005cites this paper
• Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.

  2004cites this paper
• Small Cell Lung Cancer: Treatment for Extensive Stage Disease

  2004cites this paper
• Outcomes research in lung cancer.

  2004cites this paper
• Phase II Evaluation of 96-Hour Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck (E3395): A Trial of the Eastern Cooperative Oncology Group

  2004cites this paper
• Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).

  2003cites this paper
• Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.

  2003cites this paper
• Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer.

  2003cites this paper
• Extensive-stage small-cell lung cancer.

  2003cites this paper
• Die Kosten einer supportiven Therapie mit den Granulozyten-koloniestimulierenden Faktoren (G-CSF) Lenograstim oder Filgrastim bei Patienten mit Chemotherapie-induzierter Neutropenie

  2002cites this paper
• G-CSF as prophylaxis of febrile neutropenia in SCLC

  2002influential citation
• Management of small-cell lung cancer.

  2002cites this paper
• Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia.

  2002cites this paper
• SERIES 0CONTRIBUTIONS FROM THE EUROPEAN RESPIRATORY MONOGRAPHS0 Edited by M. Decramer and A. Rossi Number 5 in this Series

  2001cites this paper
• Chemotherapy in small cell lung cancer

  2001cites this paper
• Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy

  2001cites this paper
• Chemotherapy in small cell lung cancer.

  2001cites this paper
• Treatment pathways, resource use and costs in the management of small cell lung cancer

  2001cites this paper
• Clinical Practice and Future Needs in Recombinant Human Granulocyte Colony-Stimulating Factor Treatment: A Review of Randomized Trials in Clinical Haemato-Oncology

  2001cites this paper
• Economic Issues in Lung Cancer

  2000cites this paper
• Economic issues in lung cancer.

  2000cites this paper
• Treatment and Outcomes for Elderly Patients with Small Cell Lung Cancer

  2000cites this paper
• Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. Economic Evaluation Working Group the Pediatric Oncology Group.

  2000cites this paper
• Federation of European Cancer Societies. Full report. Economic evaluation in cancer care: questions and answers on how to alleviate conflicts between rising needs and expectations and tightening budgets.

  2000cites this paper
• Management of small cell lung cancer: current state of the art.

  1999cites this paper
• Intensive Therapy of Small Cell Lung Cancer: A Review of Recently Published Data

  1999cites this paper
• Management of small cell lung cancer.

  1999cites this paper
• Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

  1999cites this paper
• The economics of febrile neutropenia: implications for the use of colony-stimulating factors.

  1998cites this paper
• Non-Curative Chemotherapy for Small Cell Lung Cancer

  1998cites this paper
• Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies.

  1998cites this paper
• Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.

  1998cites this paper
• Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.

  1998cites this paper
• First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

  1998cites this paper
• Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.

  1998cites this paper
• Economic issues in lung cancer: a review.

  1998cites this paper
• Assessing the value of a new pharmaceutical. A feasibility study of contingent valuation in managed care.

  1998cites this paper
• 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.

  1997cites this paper
• Future directions in the therapy of small cell lung cancer.

  1997cites this paper
• [Prevention and treatment of febrile neutropenia].

  1997cites this paper
• Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors.

  1997cites this paper
• Efficacy of Granulocyte-colony Stimulating Factor in Adjuvant Therapy of Malignant Gliomas

  1997cites this paper
• Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.

  1997cites this paper
• Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.

  1997cites this paper
• Cytokines: Granulocyte colony-stimulating factor

  1997cites this paper
• Time trends of consumption and costs of drugs in a cancer referral centre.

  1997cites this paper
• Small cell lung cancer in the elderly patient.

  1997cites this paper
• Dose intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer.

  1997cites this paper
• Extensive stage small cell lung cancer: determining suitability for outpatient management of febrile neutropenia.

  1996cites this paper
• Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer.

  1996cites this paper
• Hematopoietic growth factors

  1996cites this paper
• Paper one: Resource allocation in cancer medicine: Invest where the benefits are clear

  1996cites this paper
• G‐CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta‐analysis and pharmacoeconomic evaluation

  1996influential citation
• Paper two: Allocation of scarce resources: The need for critical analysis

  1996cites this paper
• Fair and effective resource allocation in cancer care: uncharted territory?

  1996cites this paper
• Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.

  1996cites this paper
• The use of growth factors with antibiotics in the setting of neutropenic fever.

  1996cites this paper
• Filgrastim (r-metHuG-CSF): the first 10 years.

  1996cites this paper
• Disconnected.

  1995cites this paper
• Section Review—Oncologic, Endocrine & Metabolic: Haematopoietic Growth Factors in Cancer Chemotherapy

  1995cites this paper
• Episodes fébriles du patient neutropénique : quelle stratégie en 1995 ?

  1995cites this paper
• Haemopoietic growth factors: uses and misuses.

  1995cites this paper
• Palliative therapy: extensive small cell lung cancer.

  1995cites this paper
• Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy.

  1995cites this paper
• Hematopoietic Growth Factors

  1995cites this paper
• A cost analysis of hematopoietic colony-stimulating factors.

  1995cites this paper
• Pharmacoeconomic Evaluation of Lenograstim and Future Directions

  1994cites this paper
• Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I.

  1994cites this paper
• Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.

  1994cites this paper
• Filgrastim Review of its Pharmacological Properties and Therapeutic Efficacy in Neutropenia

  1994cites this paper